By Finance Pulse in KeyInfo —

Rodman & Renshaw Downgrades Viracta Therapeutics

Rodman & Renshaw downgrade Viracta Therapeutics to Neutral, slashing price target from $3.50 to 25c. Key implications for healthcare and clinical trials.

A financial analyst reviewing stock charts on a sleek modern tablet, with a focus on healthcare and
Rodman & Renshaw Downgrades Viracta Therapeutics

Rodman & Renshaw downgraded Viracta Therapeutics to Neutral from Buy, lowering the price target from $3.50 to 25c.

Source